Key result
The ARB olmesartan ameliorated disease manifestations and T-cell subset imbalance in Ang II-infused hypertensive rats, whereas hydralazine did not despite comparable effects on blood pressure.
Why the study?
Does olmesartan improve the balance of helper T-cell subsets and ameliorate disease manifestations compared to hydralazine in Angiotensin II-infused hypertensive rats?
Does olmesartan improve the balance of helper T-cell subsets and ameliorate disease manifestations compared to hydralazine in Angiotensin II-infused hypertensive rats?
Angiotensin II directly induces an imbalance in helper T-cell subsets associated with hypertensive kidney injury, which is ameliorated by ARB therapy but not by nonspecific vasodilation.
No takes yet. Share an insight, caveat, or question.
May support ARB benefits beyond BP reduction in hypertensive models; hypothesis-generating and leaves open translation to humans.
Shao et al. (2003) studied Hypertensive kidney injury. Angiotensin II receptor blocker (ARB) olmesartan vs. Hydralazine was evaluated on T-cell subset balance (Th1/Th2 cytokines) and disease manifestations. The ARB olmesartan ameliorated disease manifestations and T-cell subset imbalance in Ang II-infused hypertensive rats, whereas hydralazine did not despite comparable effects on blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: